In a new publication titled “Diabetic Foot Ulcer Therapeutics Market: Global Industry Analysis and Forecast, 2016–2024,” the analysts at Persistence Market Research have targeted five key geographies and observed that the APEJ market is expected to witness the highest increase in demand base, thus registering the most attractive CAGR over the forecast period. They have further observed that competitive pricing is expected to emerge as a key trend for achieving sustainable revenue growth from the product. The expert team of analysts have further observed that acquisitions and production capacity expansion are the key differentiating strategies that manufacturers seek to follow currently. Moreover, ease of regulations, conducive business environment and presence of large patient pools are promising factors for investors to invest in the global diabetic foot ulcer therapeutics market.
The primary objective of the report is to offer updates and information related to market opportunities in the global diabetic foot ulcer therapeutics market. The report offers insights into developments in the global diabetic foot ulcer therapeutics market that are significantly transforming global businesses and enterprises. This report covers the global diabetic foot ulcer therapeutics market performance in terms of revenue contribution from various segments. The report also includes Persistence Market Research’s analysis of key trends, drivers, restraints and opportunities, which are influencing revenue growth of the global diabetic foot ulcer therapeutics market. Impact analysis of key growth drivers and restraints are included to better equip clients with crystal clear decision-making insights.
The global diabetic foot ulcer therapeutics market report begins with an overview of the market and why patients worldwide are adopting the prescribed medications. This section also underlines factors influencing the growth of the global diabetic foot ulcer therapeutics market along with a detailing of the key trends, drivers, restraints, opportunities and regulations. Impact analysis of key regional growth drivers and restraints based on the weighted average model along with key region-specific trends is included in the report to better equip clients with information and hidden insights. At the end of the report, Persistence Market Research has provided strategic recommendations for both existing and new players in the market to emerge sustainably profitable. Detailed company profiles included in this section highlight company-specific long-term and short-term strategies, key offerings and recent developments in the global diabetic foot ulcer therapeutics market.
Prevalence of diabetes and diabetic foot ulcer has been studied while assessing the global diabetic foot ulcer therapeutics market value from the demand side. The diagnosis rate, treatment rate, the adoption rate of different therapies, the price of different products is considered for top 20 countries across the globe. Indicators such as R&D expenditure, research funding from government and non-profit organizations etc. have been considered to arrive at the indicated market numbers. Yearly change in inflation rate has not been factored in while forecasting market numbers. Bottom-up approach has been used to measure market numbers for each product category, while top-down approach has been used to counter-validate the reached numbers. Historical consumption trend has been analyzed to track data.
The forecast presented in this report assesses total revenue of the global diabetic foot ulcer therapeutics market. When developing the market forecast, the starting point involves sizing the current market, which forms the basis for the forecast of how the global diabetic foot ulcer therapeutics market is anticipated to take shape in the near future. Given the characteristics of the market, the analysts have triangulated the outcome on the basis of analysis based on supply and demand sides. However, quantifying the market across the aforementioned segments and regions is more a matter of quantifying expectations and identifying opportunities rather than rationalizing them after the forecast has been completed.
The report also takes into consideration year-on-year growth to understand the predictability of the market and to identify the right opportunities across the global diabetic foot ulcer therapeutics market. As previously highlighted, the market for diabetic foot ulcer therapeutics is split into various categories. All these segments have been analyzed in terms of Basis Point Share (BPS) to understand segmental contribution to overall market growth. This detailed level of information is important to identify the various key trends in the global diabetic foot ulcer therapeutics market.
The global market for diabetic foot ulcer therapeutics is expected to represent absolute $ opportunity of more than US$ 300 Mn in 2017 over 2016 and incremental opportunity of more than US$ 5,000 Mn between 2016 and 2024. Persistence Market Research forecasts the global diabetic foot ulcer therapeutics market to grow from a little more than US$ 4,000 Mn in 2017 to reach a market valuation in excess of US$ 8,000 Mn by 2024 end. This represents a CAGR of 11.4% over the estimated period.
Rising occurrence of diabetes and rise in the incidence of diabetic foot ulcer is likely to create a positive impact on the global diabetic foot ulcer therapeutics market
A growing population affected by diabetes and a subsequent increase in the number of people afflicted with diabetic foot ulcer is likely to impact the global diabetic foot ulcer therapeutics market in a positive manner over the forecast period. Furthermore, continued prioritization to avoid surgeries and amputations is expected to fuel the growth of the global diabetic foot ulcer therapeutics market over the predicted period. Diabetes mellitus is one of the most important public health concerns worldwide, with an increased risk of developing diabetic foot ulcer. Hence, a number of clinical trials are being conducted currently wherein a large number of organizations are actively participating in extended research programs to develop novel therapies for diabetic foot ulcer treatment. Individuals with an increased risk of diabetes are demonstrating alarming hospitalization rates as a result of diabetes foot ulcer infection. This has resulted in a rise in the number of amputations. The occurrence of diabetes and associated risk factors are increasing at an alarming rate, which is expected to fuel revenue growth of the global diabetic foot ulcer therapeutics market during the period of assessment.
Major market players in the global diabetic foot ulcer therapeutics market are introducing innovative and expanded line products to retain their global market share. Over the last few decades, an increasing number of diabetic foot ulcer therapeutics manufacturers have been focusing on introducing breakthrough advanced wound dressings for diabetic foot ulcer management. This includes novel dressings with the ability to confer moisture balance with prolonged time of action, extended oxygen permeability, antimicrobial activity, growth factor stimulation, and the ability to promote autolytic debridement thus facilitating the re-epithelialization process. This factor is creating robust development in the global diabetic foot ulcer therapeutics market.
Neuro-Ischemic ulcers segment anticipated to dominate the global diabetic foot ulcer therapeutics market by ulcer type segment
By ulcer type, the Neuropathic ulcers segment is estimated to expand at a CAGR of 8.6% over the forecast period and be valued at more than US$ 3,000 Mn by 2024 end. The Ischemic ulcers segment was estimated to account for more than 5% revenue share of the global diabetic foot ulcer therapeutics market by 2016 end and is expected to gain a little more than 40 BPS in its market share by 2024 over 2016. Revenue from the Ischemic ulcers segment is projected to increase at a CAGR of 12% over 2016–2024, to reach more than US$ 500 Mn by 2024. The Neuro-Ischemic ulcers segment was estimated to account for a market value share of close to 40% in the global diabetic foot ulcer therapeutics market by 2016 end and is expected to gain more than 500 BPS in its market share by 2024 over 2016.